Here are five things to know:
1. On Feb. 15, six analysts gave the shares a “strong buy” rating and three analysts gave the shares a “buy” rating.
2. Six analysts gave the shares a “neutral” rating.
3. Integra LifeSciences Holdings has a 50-day moving average of $62.57 and 200-day moving average of $62.29.
4. The market cap is $2.05 billion.
5. During the last trading session, the shares were down 0.07 percent.
More articles on devices:
ConforMIS reports Q4, full year results — 12 things to know
Hip, knee orthopedic surgical implants market to reach $33M by 2022: 3 takeaways
National Government Services establishes positive coverage for MIS SI joint fusion: 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
